Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Am J Physiol Regul Integr Comp Physiol ; 326(3): R242-R253, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38284128

ABSTRACT

The estrous cycle is known to modify food, fluid, and electrolyte intake behaviors and energy homeostasis in various species, in part through fluctuations in estrogen levels. Simultaneously, commonly commercially available rodent dietary formulations greatly vary in soy protein content, and thereby the delivery of biologically active phytoestrogens. To explore the interactions among the estrous cycle, sodium, fluid, and caloric seeking behaviors, and energy homeostasis, young adult C57BL/6J female mice were maintained on a soy protein-free 2920x diet and provided water, or a choice between water and 0.15 mol/L NaCl drink solution. Comprehensive metabolic phenotyping was performed using a multiplexed Promethion (Sable Systems International) system, and estrous stages were determined via daily vaginal cytology. When provided food and water, estrous cycling had no major modulatory effects on intake behaviors or energy balance. When provided a saline solution drink choice, significant modulatory effects of the transition from diestrus to proestrus were observed upon fluid intake patterning, locomotion, and total energy expenditure. Access to saline increased total daily sodium consumption and aspects of energy expenditure, but these effects were not modified by the estrous stage. Collectively, these results indicate that when supplied a phytoestrogen-free diet, the estrous cycle has minor modulatory effects on ingestive behaviors and energy balance in C57BL/6J mice that are sensitive to sodium supply.NEW & NOTEWORTHY When provided a phytoestrogen-free diet, the estrous cycle had very little effect on food and water intake, physical activity, or energy expenditure in C57BL/6J mice. In contrast, when provided an NaCl drink in addition to food and water, the estrous cycle was associated with changes in intake behaviors and energy expenditure. These findings highlight the complex interactions among estrous cycling, dietary formulation, and nutrient presentation upon ingestive behaviors and energy homeostasis in mice.


Subject(s)
Phytoestrogens , Sodium Chloride , Mice , Female , Animals , Phytoestrogens/pharmacology , Mice, Inbred C57BL , Estrous Cycle , Diet , Energy Metabolism , Sodium , Water
2.
Am J Perinatol ; 35(10): 994-1000, 2018 08.
Article in English | MEDLINE | ID: mdl-29486497

ABSTRACT

OBJECTIVE: To implement and evaluate a clinical practice algorithm to identify preterm infants with sodium deficiency and guide sodium supplementation based on urine sodium concentrations. STUDY DESIGN: Urine sodium concentration was measured in infants born at 260/7 to 296/7 weeks' gestation at 2-week intervals. Sodium supplementation was based on the urine sodium algorithm. Growth and respiratory outcomes in this cohort were compared with a matched cohort cared for in our neonatal intensive care unit prior to algorithm implementation (2014-2015 cohort). RESULTS: Data were compared for 50 infants in the 2014-2015 cohort and 40 infants in the 2016 cohort. Urine sodium concentration met criteria for supplementation in 75% of the 2016 cohort infants within the first 4 weeks after birth. Average daily sodium intake was greater in the 2016 cohort compared with the 2014-2015 cohort (p < 0.05). Caloric, protein, and total fluid intakes were similar between cohorts. The change in weight Z-score between 2 and 8 weeks of age was significantly greater in the 2016 versus 2014-2015 cohort (0.32 ± 0.05 vs. -0.01 ± 0.08; p < 0.01). No impact on respiratory status at 28 days of age or 36 weeks of postmenstrual age was identified. CONCLUSION: Institution of a clinical practice algorithm to instruct clinicians on sodium supplementation in preterm infants may improve growth outcomes.


Subject(s)
Body Weight , Dietary Supplements , Infant, Extremely Premature/urine , Sodium/administration & dosage , Sodium/urine , Algorithms , Cohort Studies , Female , Gestational Age , Humans , Hyponatremia/diagnosis , Infant , Infant, Extremely Premature/growth & development , Infant, Newborn , Male
3.
Pediatr Res ; 80(2): 244-51, 2016 08.
Article in English | MEDLINE | ID: mdl-27049292

ABSTRACT

BACKGROUND: Neonatal growth restriction (nGR) leads to leptin deficiency and increases the risk of hypertension. Previous studies have shown nGR-related hypertension is normalized by neonatal leptin (nLep) and exacerbated by psychological stress. With recent studies linking leptin and angiotensin signaling, we hypothesized that nGR-induced nLep deficiency increases adult leptin sensitivity; leading to leptin- or stress-induced hypertension, through a pathway involving central angiotensin II type 1 receptors. METHODS: We randomized mice with incipient nGR, by virtue of their presence in large litters, to vehicle or physiologic nLep supplementation (80 ng/g/d). Adult caloric intake and arterial pressure were monitored at baseline, during intracerebroventricular losartan infusion and during systemic leptin administration. RESULTS: nGR increased leptin-triggered renal sympathetic activation and hypertension with increased leptin receptor expression in the arcuate nucleus of the hypothalamus; all of those nGR-associated phenotypes were normalized by nLep. nGR mice also had stress-related hyperphagia and hypertension, but only the stress hypertension was blocked by central losartan infusion. CONCLUSION: nGR leads to stress hypertension through a pathway that involves central angiotensin II receptors, and nGR-associated leptin deficiency increases leptin-triggered hypertension in adulthood. These data suggest potential roles for preservation of neonatal growth and nLep supplementation in the prevention of nGR-related hypertension.


Subject(s)
Growth Disorders/blood , Leptin/blood , Leptin/deficiency , Receptors, Angiotensin/blood , Sympathetic Nervous System/physiopathology , Angiotensins/metabolism , Animals , Blood Pressure/physiology , Disease Models, Animal , Growth Disorders/complications , Hypertension/blood , Hypertension/complications , Hypertension/physiopathology , Losartan/pharmacology , Male , Mice , Mice, Inbred C57BL , Random Allocation , Renin-Angiotensin System/physiology , Signal Transduction , Stress, Psychological/complications
4.
J Mol Cell Cardiol ; 37(1): 33-41, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15242733

ABSTRACT

Glutamate is the only amino acid extracted by healthy myocardium in net amounts, with uptake further increased during hypoxic or ischemic conditions. Glutamate supplementation provides cardioprotection from hypoxic and reperfusion injury through several metabolic pathways that depend upon adequate transport of glutamate into the mitochondria. Glutamate transport across the inner mitochondrial membrane is a key component of the malate/aspartate shuttle. Glutamate transport in the brain has been well characterized since the discovery of the excitatory amino acid transporter (EAAT) family. We hypothesize that a protein similar to EAAT1 found in brain may function as a glutamate transporter in cardiac mitochondria. Rat heart total RNA was screened by reverse transcriptase-polymerase chain reaction with an array of primer pairs derived from the rat brain EAAT1 cDNA sequence, yielding a 3786-bp cDNA comprising a 1638-bp open reading frame identical to rat brain EAAT1 with flanking 5'- and 3'-untranslated regions. Northern blot analysis confirmed a 4-kb mRNA product in rat heart and brain, with greater abundance in brain. A protein of the predicted approximate 60-kD size was recognized in myocardial lysates by an anti-EAAT1 polyclonal antibody produced against an amino-terminal peptide from human EAAT1. The protein enriched in rat heart mitochondria by immunoblot, co-localized with the mitochondrial protein cytochrome c by immunohistochemistry, and further localized to the inner mitochondrial membrane upon digitonin fractionation of the mitochondria. In myocytes overexpressing EAAT1, activity of the malate/aspartate shuttle increased by 33% compared to non-transfected cells (P = 0.004). These data indicate that EAAT1 is expressed in myocardial mitochondria, and functions in the malate/aspartate shuttle, suggesting a role for EAAT1 in myocardial glutamate metabolism.


Subject(s)
Brain/pathology , Excitatory Amino Acid Transporter 1/biosynthesis , Excitatory Amino Acid Transporter 1/physiology , Mitochondria, Heart/metabolism , Adenoviridae/genetics , Animals , Aspartic Acid/metabolism , Blotting, Northern , Brain/metabolism , Cells, Cultured , Coloring Agents/pharmacology , Cytochromes c/metabolism , DNA, Complementary/metabolism , Digitonin/pharmacology , Genetic Vectors , Glutamic Acid/therapeutic use , Hypoxia , Immunoblotting , Immunohistochemistry , Malates/metabolism , Microscopy, Fluorescence , Mitochondria/pathology , Myocardium/pathology , Open Reading Frames , RNA/metabolism , RNA, Messenger/metabolism , Rats , Rats, Inbred WKY , Rats, Sprague-Dawley , Reperfusion Injury , Reverse Transcriptase Polymerase Chain Reaction , Subcellular Fractions , Tetrazolium Salts/pharmacology , Thiazoles/pharmacology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL